Pharma R&D Today

SciBite’s James Malone Talks Future of Biocuration on Conference Panel

Posted on April 15th, 2021 by Lauren Barham

Biocurators are among the unsung heroes of the life sciences world, performing the essential task of translating and integrating biomedical information into interoperable databases. Of course, there is a lot more to it than that, as attendees of the International Society for Biocuration’s 14^th Annual Biocuration Conference already know.

Reaxys Prize Winners Share Their Research Experiences and Advice

Posted on April 13th, 2021 by Ann-Marie Roche

If there is one thing we at Elsevier have learned over the last 10 years of hosting the Reaxys PhD Prize, it’s that there are many different paths to research success. We have seen incredible work from scientists coming from a variety of backgrounds and experiences, and that was again evident with our three winning finalists for the 2020 Reaxys PhD Prize.

Beyond Reference Management: How Literature Management is a Win for the Life Science Organization

Posted on April 7th, 2021 by Heather Desmarais, MLS

Scientific literature is a critical component to virtually all aspects of a life science enterprise, including Medical Affairs, Pharmacovigilance and R&D. However, the process of curating and sharing literature can lead to significant challenges in organizing content, facilitating collaboration and enforcing copyright compliance.

COVID-19 Treatment Trial Reaches Out to Communities of Color

Posted on April 5th, 2021 by Ann-Marie Roche

An ongoing problem in clinical trials over the years has been a failure to procure diverse enough representation among the participants. For a long time, this was due to bias and oversight on the part of the research community, and the consequence was a lack of full understanding in how medications and treatments affected women and various racial/ethnic minorities.

phactMI: Delivering accurate drug information to point of care, part II

Posted on March 31st, 2021 by Tom Williams

Part 2: The challenges that can restrict access to the latest and most accurate information on medications

Healthcare professionals are the ones tasked with safely prescribing, dispensing and managing medications. As mentioned in part 1 of this series, that puts them in the position of needing to know — or being able to quickly check — the latest information about a huge number of new and existing medical products.

FDA Introduces Data Modernization Action Plan

Posted on March 29th, 2021 by Ann-Marie Roche

One of the frustrations of our Big Data era is that, despite the existence of an ever-growing wealth of valuable data, this data is often stuck in different silos. This lack of accessibility makes it hard to get the most out of data that has the potential to be extremely useful.

About this Blog

The Elsevier Pharma R&D blog provides insight and opinion on topics related to pharmaceutical research and development, namely: big data, target identification, new drug discovery, drug safety monitoring, risk mitigation and regulatory compliance. We serve the community of chemists, scientists, drug safety specialists, educators and students interested in pharmaceutical R&D.

Editor’s note: The views and opinions expressed are those of the author and do not necessarily reflect the views of Elsevier,  its affiliates and sponsors or its parent company, Reed Elsevier.